Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

glenmark arzneimittel gmbh - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - azacitidin - pulver til injektionsvæske, suspension - 25 mg/ml

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastiske midler - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - tezacaftor, ivacaftor - cystisk fibrose - andet respirationssystem produkter - symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (cf) aged 6 years and older who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - azacitidin - leukæmi, myeloid, akut - antineoplastiske midler - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - insulin human - insuliner og analoger til injektion, intermediært virkende - cats; dogs - til behandling af diabetes mellitus hos katte og hunde til at opnå reduktion af hyperglykæmi og forbedring af de tilknyttede kliniske tegn.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alcon nordic a/s - tropicamid - øjendråber, opløsning - 0,5%

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alcon nordic a/s - tropicamid - øjendråber, opløsning - 1%

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medac, gesellschaft für klinische spezialpräparate mbh - dacarbazincitrat - pulver til injektions-/infusionsvæske, opløsning - 200 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vertex pharmaceuticals (ireland) limited - ivacaftor, tezacaftor, elexacaftor - cystisk fibrose - andet respirationssystem produkter - kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (cf) in patients aged 6 years and older who have at least one f508del mutation in the cystic fibrosis transmembrane conductance regulator (cftr) gene.